Abstract
The purpose of this paper is to provoke careful and continuing reconsideration of the relationship between psychiatrists and the pharmaceutical industry through historical analysis of trends in the promotion of psychotropic drugs. Psychiatrists remain concerned about the relationship of the profession with the pharmaceutical industry. From examination of my own extended experience of that relationship (including as a former Royal Australian and New Zealand College of Psychiatrists General Councilor and chair of the Clinical Practice Advisory and Ethical Practice Committees), attention is drawn to the influence of the industry on the categorization and naming of drugs, attempts to propose target disorders and the obsolescence of established agents. Caution in accepting the role of 'opinion leader' is recommended but it remains important for psychiatrists to continue to ethically engage with the industry.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
